Cargando…

Pharmacogenomics of statins: understanding susceptibility to adverse effects

Statins are a cornerstone of the pharmacologic treatment and prevention of atherosclerotic cardiovascular disease. Atherosclerotic disease is a predominant cause of mortality and morbidity worldwide. Statins are among the most commonly prescribed classes of medications, and their prescribing indicat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitzmiller, Joseph P, Mikulik, Eduard B, Dauki, Anees M, Murkherjee, Chandrama, Luzum, Jasmine A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055044/ https://www.ncbi.nlm.nih.gov/pubmed/27757045 http://dx.doi.org/10.2147/PGPM.S86013

Ejemplares similares

Editorial: Pharmacogenomics of Adverse Drug Reactions
por: Siddiqui, Moneeza K., et al.
Publicado: (2022)

Candidate‐Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol‐Lowering Response to Simvastatin
por: Kitzmiller, JP, et al.
Publicado: (2016)

Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review
por: Yow, Hui-Yin, et al.
Publicado: (2023)

Pharmacogenomics of COVID-19 therapies
por: Takahashi, Takuto, et al.
Publicado: (2020)

Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants
por: Talameh, Jasmine A, et al.
Publicado: (2014)

Focus on pharmacogenomics, phytonutrient-drug interactions and COVID-19 vaccines: Perspectives on ADRs, ADEs, and SEDs
por: Ray, Sidhartha D., et al.
Publicado: (2021)

Focus on pharmacogenomics, phytonutrient–drug interactions and COVID-19 vaccines: Perspectives on ADRs, ADEs, and SEDs
por: Ray, Sidhartha D., et al.
Publicado: (2022)

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort
por: Kitzmiller, Joseph P., et al.
Publicado: (2014)

Pharmacogenomic insights into treatment and management of statin-induced myopathy
por: Peters, Bas JM, et al.
Publicado: (2009)

Pharmacogenomics of adverse drug reactions
por: Daly, Ann K
Publicado: (2013)

Pharmacogenomics of chemotherapeutic susceptibility and toxicity
por: Moen, Erika L, et al.
Publicado: (2012)

Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial
por: Murphy, William A., et al.
Publicado: (2022)

Pharmacogenomics and adverse drug reactions in children
por: Rieder, Michael J., et al.
Publicado: (2014)

Statins Neuromuscular Adverse Effects
por: Attardo, Silvia, et al.
Publicado: (2022)

Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins
por: van Leeuwen, Jenna E., et al.
Publicado: (2022)

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions
por: Cacabelos, Ramón, et al.
Publicado: (2021)

Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing
por: Canestaro, William J., et al.
Publicado: (2012)

Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components
por: Turner, Richard Myles, et al.
Publicado: (2019)

Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin
por: Mitchell, Dominic, et al.
Publicado: (2016)

A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam
por: Campbell, Ciarán, et al.
Publicado: (2022)

Oral Glucose Tolerance Test: An Informative Endpoint or an Added Burden in Metformin Drug–Drug Interaction Studies?
por: Dauki, Anees M., et al.
Publicado: (2022)

Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics
por: van Manen, Daniëlle, et al.
Publicado: (2012)

Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?
por: Luzum, Jasmine A., et al.
Publicado: (2016)

Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing
por: Floyd, James S., et al.
Publicado: (2019)

Review on Databases and Bioinformatic Approaches on Pharmacogenomics of Adverse Drug Reactions
por: Tong, Hang, et al.
Publicado: (2021)

The Apportionment of Pharmacogenomic Variation: Race, Ethnicity, and Adverse Drug Reactions
por: Jordan, I. King, et al.
Publicado: (2022)

Understanding the molecular mechanisms of statin pleiotropic effects
por: German, Charles A., et al.
Publicado: (2023)

Statin-induced necrotizing autoimmune myopathy: an extremely rare adverse effect from statin use
por: Sharma, Priyadarshani, et al.
Publicado: (2019)

A Mechanism for Statin-Induced Susceptibility to Myopathy
por: Lotteau, Sabine, et al.
Publicado: (2019)

Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation
por: Su, Shih-Chi, et al.
Publicado: (2016)

Opioid Therapy Pharmacogenomics for Noncancer Pain: Efficacy, Adverse Events, and Costs
por: Xu, Yan, et al.
Publicado: (2013)

The pharmacogenomics of carbamazepine-induced cutaneous adverse drug reaction in the South of Vietnam
por: Nguyen, Ai-Hoc, et al.
Publicado: (2023)

BNP and Precision Medicine: Tip of an Iceberg
por: Lanfear, David E., et al.
Publicado: (2021)

Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation
por: King, Charlotte, et al.
Publicado: (2020)

Pharmacogenomics and Morphine
por: Ofoegbu, Adaku, et al.
Publicado: (2021)

Pharmacogenomics
Publicado: (2008)

Pharmacogenomics
Publicado: (2008)

Association of Valproic Acid Use With Post-Myocardial Infarction Heart Failure Development: A Meta-Analysis of Two Retrospective Case–Control Studies
por: English, Joseph D, et al.
Publicado: (2022)

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics
por: Mizzi, Clint, et al.
Publicado: (2016)

Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms
por: Dao, Ro-Lan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_218q4dbaf7kkflahfrlnoevt2v